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Mechanisms of hypoxic gene regulation of angiogenesis factor
Cyr61 in melanoma cells
Abstract
Hypoxia has a profound influence on progression and metastasis of malignant tumors. In the present
report, we used the oligonucleotide microarray technique to identify new hypoxia-inducible genes in
malignant melanoma with a special emphasis on angiogenesis factors. A commercially available
Affymetrix gene chip system was used to analyze five melanoma cell lines of different aggressiveness.
A total of 160 hypoxia-inducible genes were identified, clustering in four different functional clusters. In
search of putative angiogenesis and tumor progression factors within these clusters, Cyr61, a recently
discovered angiogenesis factor, was identified. Cyr61 was hypoxia-inducible in low aggressive
melanoma cells; however, it showed constitutive high expression in highly aggressive melanoma cells.
Further analyses of transcriptional mechanisms underlying Cyr61 gene expression under hypoxia
demonstrated that an AP-1 binding motif within the Cyr61 promoter plays a central role in the hypoxic
regulation of Cyr61. It could be shown by use of in vitro luciferase assays, electrophoretic mobility shift
assays, and immunoprecipitation that hypoxia-inducible factor-1alpha interacts with c-Jun/AP-1 and
may thereby contribute to Cyr61 transcriptional regulation under hypoxia. Taken together, the presented
data show that Cyr61 is a hypoxia-inducible angiogenesis factor in malignant melanoma with tumor
stage-dependent expression. This may argue for a hypoxia-induced selection process during tumor
progression toward melanoma cells with constitutive high Cyr61 expression.
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Hypoxia has a profound influence on progression and
metastasis of malignant tumors. In the present report,
we used the oligonucleotide microarray technique to
identify new hypoxia-inducible genes in malignant mel-
anoma with a special emphasis on angiogenesis factors.
A commercially available Affymetrix® gene chip system
was used to analyze five melanoma cell lines of different
aggressiveness. A total of 160 hypoxia-inducible genes
were identified, clustering in four different functional
clusters. In search of putative angiogenesis and tumor
progression factors within these clusters, Cyr61, a re-
cently discovered angiogenesis factor, was identified.
Cyr61 was hypoxia-inducible in low aggressive mela-
noma cells; however, it showed constitutive high expres-
sion in highly aggressive melanoma cells. Further anal-
yses of transcriptional mechanisms underlying Cyr61
gene expression under hypoxia demonstrated that an
AP-1 binding motif within the Cyr61 promoter plays a
central role in the hypoxic regulation of Cyr61. It could
be shown by use of in vitro luciferase assays, electro-
phoretic mobility shift assays, and immunoprecipitation
that hypoxia-inducible factor-1 interacts with c-Jun/
AP-1 and may thereby contribute to Cyr61 transcrip-
tional regulation under hypoxia. Taken together, the
presented data show that Cyr61 is a hypoxia-inducible
angiogenesis factor in malignant melanoma with tumor
stage-dependent expression. This may argue for a hy-
poxia-induced selection process during tumor progres-
sion toward melanoma cells with constitutive high
Cyr61 expression.
It is well accepted that local growth and metastasis of a large
variety of malignant tumors are dependent on neoangiogenesis
(1–3). The process of tumor angiogenesis is largely based on the
production and secretion of so-called angiogenesis factors such
as vascular endothelial growth factor (VEGF),1 fibroblast
growth factor, and interleukin (IL)-8 (3–5). However, the mech-
anisms of angiogenesis factor production are still poorly under-
stood. Evidence has been provided that a constitutive high
expression of angiogenesis factors in isolated tumor cells or cell
clones may be the first step in a selection process toward
angiogenesis factor-producing tumors (6). This constitutive
high expression in tumor cells may derive from the so-called
“angiogenic switch,” which is supposed to happen very early
during tumor development initiating a selection process (for
review, see Ref. 2). In accordance with this, it has been shown
that a constitutive high expression of IL-8 promotes tumor
growth of melanoma cells in vivo (7, 8). However, the molecular
mechanisms underlying the induction of the angiogenic switch
in tumors have not been defined so far.
More recent investigations have emphasized that the specific
conditions of the tumor microenvironment may have a strong
impact on the secretion of angiogenesis factors. In particular,
tissue hypoxia has been shown to play a key role for the
induction of these factors (9–11). Interestingly, even after neo-
vascularization, tumor areas may remain under low oxygen
tension, because of inadequate vascularization after neoangio-
genesis (12). Thus, hypoxic areas remain a constant feature of
malignant tumors and metastases. Up to now a large series of
angiogenesis factors have been identified to be inducible by
hypoxia. Among these are fibroblast growth factor, VEGF,
platelet-derived growth factor, IL-8, and angiogenin (13–19).
The majority of these factors had also been shown to be hy-
poxia-inducible and expressed in malignant melanoma (15, 17,
19, 20).
The recent findings about hypoxia-inducible gene expression
have fostered further molecular analyses of gene regulatory
mechanisms in tumor cells under hypoxia (21–27). It could be
shown that the transcription factors AP-1 and hypoxia-induc-
ible factor (HIF)-1 are major contributors to gene transcrip-
tion of hypoxia-inducible genes (21, 24–27). In search for fur-
ther upstream activators, signal transduction cascades
interfering with transcription factors were analyzed in more
detail. It could be shown that protein kinase C and the stress
signaling pathway of c-Jun N-terminal kinase might play a
central role in hypoxic signaling (28–30). However, the mech-
anisms underlying hypoxic signal transduction are still poorly
defined.
In the present report we used the oligonucleotide microarray
technique to analyze the gene expression pattern of malignant
melanoma cells in search for new hypoxia-inducible genes in-
* This work was supported by German Bundesministerium fu¨r Bil-
dung und Forschung Grant O31U214A (to M. K. and M. O. G.). The
costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked “adver-
tisement” in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
§ To whom correspondence should be addressed: Dept. of Dermatol-
ogy and Venereology, University of Rostock, Augusten Str. 80, 18055
Rostock, Germany. Tel.: 49-381-4949708; Fax: 49-381-4949702; E-mail:
manfred.kunz@med.uni-rostock.de.
1 The abbreviations used are: VEGF, vascular endothelial growth
factor; ECL, enhanced chemiluminescence; DMRIE-CTM, 1,2-dimyri-
styloxypropyl-3-dimethylhydroxyethyl ammonium bromide; EMSA,
electrophoretic mobility shift assay; HIF-1, hypoxia-inducible factor-
1; AP-1, activator protein-1; ARNT, aryl hydrocarbon receptor nuclear
translocator; CTGF, connective tissue growth factor; STAT-1, signal
transducer and activator of transcription-1; Ab, antibody; IL, interleu-
kin; PMA, phorbol 12-myristate 13-acetate; MEKK, mitogen-activated
extracellular signal-regulated protein kinase kinase; GST, glutathione
S-transferase; CMV, cytomegalovirus; MOPS, 4-morpholinepropane-
sulfonic acid; MES, 4-morpholineethanesulfonic acid; FCS, fetal calf
serum.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 278, No. 46, Issue of November 14, pp. 45651–45660, 2003
© 2003 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org 45651
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on July 3, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
volved in tumor angiogenesis. It could be shown that Cyr61, a
recently discovered angiogenesis factor, is hypoxia-inducible in
malignant melanoma cells. Moreover, Cyr61 showed a tumor
stage-dependent expression with a constitutive strong expres-
sion in highly aggressive melanoma cell lines. The underlying
mechanisms of its transcriptional regulation under hypoxia
were further studied. We demonstrated that AP-1 and HIF-1
may both contribute to hypoxia-induced gene expression
of Cyr61.
MATERIALS AND METHODS
Plasmids—The following plasmid constructs were used for co-trans-
fection studies in in vitro luciferase assays: pRc/CMV, pRc/CMV-HIF-
1, and pARNT/CMV4. The pRc/CMV plasmid (empty control vector)
was purchased from Invitrogen (Leek, The Netherlands); the pRc/CMV-
HIF-1 vector was generated by cloning of HIF-1 cDNA into the
pRc/CMV vector. The pARNT/CMV4 plasmid (31, 32) carrying the
ARNT cDNA was kindly provided by L. Poellinger (Karolinska Insti-
tute, Stockholm, Sweden).
Cell Lines and Culture Conditions—The human melanoma cell lines
1F6, 530, Mel57, BLM, and MV3 were kindly provided by G. van Muijen
(Institute of Pathology, University of Nijmegen, Nijmegen, The Neth-
erlands). The metastatic potential of these cell lines has been investi-
gated in nude mice. The cell lines 530 and 1F6 represent low aggressive,
non-metastatic cell lines; the cell line Mel57 has been characterized as
intermediate to highly aggressive; and BLM and MV3 are both highly
aggressive, metastatic cell lines (33–35). Melanoma cell lines and Jur-
kat cells (which were used in control experiments) were maintained in
RPMI 1640 medium (Linaris, Bettingen, Darmstadt, Germany), sup-
plemented with 10% fetal calf serum (FCS; Linaris), 2 mM L-glutamine,
100 units/ml penicillin/streptomycin, and 1% nonessential amino acids.
Cells were cultured in a humidified incubator (37 °C in 5% CO2, 95%
air). For hypoxic treatment cultures were transferred for different time
periods to hypoxic culture conditions (1% O2; mentioned as hypoxia) in
an hypoxic incubator as described previously (32). Harvesting of cells
was also performed under hypoxic conditions to avoid reoxygenation
artifacts. Parallel cultures were constantly kept under normal oxygen
conditions (mentioned as normoxia). H-Ras-transformed wild type
mouse embryonic fibroblasts (MEF-HIF/) and HIF-1-null mouse
embryonic fibroblasts (MEF-HIF/) (36) were kept in Dulbecco’s mod-
ified Eagle’s medium supplemented with 10% fetal calf serum and 100
units/ml penicillin/streptomycin.
RNA Extraction and Gene Chip Hybridization—Melanoma cell lines
530, 1F6, Mel57, BLM, and MV3, respectively, were kept under nor-
moxic conditions or exposed to 24 h of hypoxia (1% oxygen). Total RNA
was isolated using the total RNeasy kit (Qiagen, Hilden, Germany).
RNA concentrations were determined spectrophotometrically at 260
nm. Probes for chip hybridization derived from isolated RNA samples
were generated according to the instructions from the supplier (Af-
fymetrix, Santa Clara, CA). The HuGeneFL ArrayTM (Affymetrix) with
a capacity of 5600 human full-length characterized genes was used for
mRNA expression profiling. Hybridization and washing of gene chips
were performed according to the instructions from the supplier and as
described earlier by Lockhart and co-workers (37). A laser scanner
(Hewlett-Packard Gene ScannerTM) was used for analysis of gene chips,
and the expression levels were calculated using a commercially avail-
able software provided by Affymetrix (Microarray Suite®).
Biostatistical Analysis of Gene Chip Data—Before cluster analysis
genes were pre-selected for those that showed increased expression
under hypoxia in at least one out of five cell lines to encompass all
hypoxia-inducible genes of our experiments. Pre-selection resulted in a
list of 1349 candidate genes. These were subjected to hierarchical clus-
tering using Eisen software as recently described (38). Clustering tools
were downloaded from www.rana.lbl.gov/EisenSoftware.htm. Hierar-
chical clustering was performed using average linkage differences. The
“-fold change” of gene expression under hypoxia was used as clustering
parameter. By this means four different clusters (cluster I–IV) were
generated overall covering 160 genes. Cluster IV was re-clustered to
analyze absolute gene expression with the average difference (repre-
senting the absolute value of gene expression) as clustering parameter.
In the latter analyses, gene expression values were normalized to the
mean value of all genes in this experiment.
Generation of a Cyr61 cDNA Probe—A Cyr61 cDNA probe for North-
ern hybridization was generated by reverse transcriptase-PCR. For this
purpose total RNA was extracted from BLM melanoma cells using the
total RNeasy kit (Qiagen). One  g of total RNA was reverse transcribed
by superscript reverse transcriptase (Invitrogen, Eggenstein, Germany)
using hexamer priming. Primers for PCR amplification were purchased
from ARK Scientific Biosystems (Darmstadt, Germany). These had the
following recently published sequences (39): 5 primer, 5-TGTGGAA-
CTGGTATCTCCACACGA-3; 3 primer, TCTTTTCACTGAATATAAA-
ATTAAAA-3. PCR amplification generated a cDNA probe of 1039 bp
length. PCR conditions: an initial 5-min denaturation step was followed
by 10 cycles of 30 s of denaturation at 94 °C, 30 s of annealing at 58 °C,
1 min of primer extension at 72 °C. After that, 20 cycles of 30 s of
denaturation at 94 °C, 30 s of annealing at 60 °C, and 1 min of primer
extension at 72 °C were carried out. A terminal primer extension step of
10 min at 72 °C was added. The PCR products were separated by
agarose gel electrophoresis. The specific fragment of 1039 bp was cut
out, purified using the QIAExII gel extraction kit (Qiagen), cloned into
the pGEM-T vector (Promega, Heidelberg, Germany), and sequenced
using an automated capillary sequencer (PerkinElmer, Weiterstadt,
Germany). For Northern hybridization the cDNA probe was cut out
from the pGEM-T vector by restriction enzyme digest and radioactively
labeled.
RNA Extraction and Northern Blot Analysis—Total cytoplasmic
RNA was isolated using the total RNeasy kit (Qiagen). RNA concentra-
tion was determined spectrophotometrically at 260 nm. Fifteen micro-
grams of RNA/sample were denatured in 50% formamide in gel running
buffer (0.1 M MOPS, pH 7.0, 40 mM sodium acetate, 5 mM EDTA, pH 8.0)
for 15 min at 65 °C, fractionated on a 1% agarose gel in formaldehyde
buffer, and subsequently transferred to a nylon membrane (Hybond N,
Amersham Biosciences) in 20 SSC. As a probe for Cyr61 mRNA, a
specific 1039 cDNA fragment was used. For Northern hybridization the
purified fragment was labeled to high specific activity with [32P]dATP
using a random primer labeling system (Roche Molecular Biochemicals,
Mannheim, Germany). Membranes were cross-linked by ultraviolet
light irradiation and prehybridized in a dextran sulfate buffer (100
g/liter dextran sulfate, 0.6 M NaCl, 0.2 M Na2HPO4, 6 mM EDTA, 1.75%
lauroylsarcosinate, 50 g/ml salmon sperm DNA, pH 6.2) for 1 h at
65 °C. Hybridization was carried out in the same prehybridization
solution containing 5 106 cpm/ml of labeled probe. After hybridization
for 16 h at 65 °C and 6 h at 60 °C, membranes were washed twice with
2 SSPE, 0.1% sodium dodecyl sulfate (SDS) at room temperature;
once with 1 SSPE, 0.1% SDS at 60 °C; and once again with 0.2
SSPE, 0.1% SDS. Membranes were then exposed to HyperfilmTM (Am-
ersham Biosciences) with intensifying screens at 80 °C for 3 days.
Northern blots for ribosomal L28 RNA were performed, which served as
control for equal loading (40).
Generation of Cyr61 Promoter Luciferase Constructs—A 883-bp and a
605-bp fragment, respectively, of the recently published promoter re-
gion of the Cyr61 gene (Ref. 41; EMBL GenBankTM, accession no.
HSA249826) were generated by PCR amplification. The first fragment
covers almost the complete Cyr61 promoter region of 935 bp beginning
at the transcription start site. Further 5 sequences (beyond position
883) carry no binding motifs for known transcription factors. The
second fragment (605 bp) covers the promoter region (also beginning at
the transcription start site) ending immediately downstream of an AP-1
binding motif (TGACTCA) at position624. For fragment generation of
the Cyr61 promoter, genomic DNA was isolated from BLM melanoma
cells using a commercially available DNA isolation kit (Qiagen). PCR
amplification was carried out using the following primers: 883-bp frag-
ment: 5 primer (5-CGGGTACCTAAAGTGGGAACCTCCA-3) and 3
primer (5-CCGCTCGAGTCTCGCTCGCGGTCTGCC-3); 605-bp frag-
ment: 5 primer (5-CGGGGTACCTCTTCCCCGTTCTACTC-3) and 3
primer (5-CCGCTCGAGTCTCGCTCGCGGTCTGCC-3). Both pairs of
primers generated a KpnI restriction site at the 5 end and an XhoI
restriction site at the 3 end of the amplified fragments. These sites
were used for further cloning of the fragments into the pGL3 vector
(Promega, Heidelberg, Germany). The pGL3 promoter constructs were
sequenced using an automated capillary sequencer (PerkinElmer Life
Sciences). The promoter construct carrying the 883-bp fragment was
termed cyr-900-luc, and the promoter construct with the 605-bp con-
struct was termed cyr-600-luc.
In Vitro Mutagenesis of Cyr61 Promoter—In vitro mutagenesis was
performed to generate mutated cyr-900-luc constructs. A promoter con-
struct with a mutated AP-1 binding motif was termed cyr-900APmut-
luc. A promoter construct where all four HRE-like motifs (position 68,
371, 400, 653) mutated was termed cyr-900HIFmut-luc. For mu-
tagenesis of the AP-1 binding motif, TGACTCA, this motif was changed
to TGACTAC, which results in an inhibition of transcription factor
binding (42). For mutagenesis of the four HRE-like binding motifs,
present on the promoter as CACG, this motif was changed to CTTT. A
commercially available mutagenesis kit was used (QuikChangeTM site-
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directed mutagenesis kit, Stratagene, La Jolla, CA), and mutagenesis
was performed according to the specifications from the manufacturer.
The mutagenesis primers used were as follows.
For AP-1 motif mutagenesis, primers were 5-GAAGTCCA-
CAAATATTCCTGACTACGAGACACACTCCTC-3 and 5-GAGGAGT-
GTGTCTCGTAGTCAGGAATATTTGTGGACTTC-3. For mutagenesis
of HRE-like motifs at position 68, primers were 5-ACGTCACTG-
CAACTTTCGGCGCCTCCGC-3 and 5-GCGGAGGCGCCGAAAGTTG-
CAGTGACGT-3; at position 371, 5-CATCACCACCATCTTTC-
CCAAAGAACC-3 and 5-GGTTCTTTGGGGAAAGATGGTGGTGATG-
3; at position 400, 5-CCCCTCGCCCCTCTTTACCCTCCAACTA-3
and 5-TAGTTGGAGGGTAAAAGGGGCGAGGGG-3; and at position
653, 5-ACTTGTTCCGAACTTTCCTCTTTGAAGT-3 and 5-ACT-
TCAAAGAGGAAAGTTCGGAACAAGT-3.
Successful mutagenesis was confirmed by sequencing using an au-
tomated capillary sequencer (PerkinElmer Life Sciences).
In Vitro Luciferase Assays—Cyr61 promoter luciferase constructs
were used for in vitro luciferase assays. For this purpose the melanoma
cell line 1F6 was transfected with 2 g of plasmid DNA (of wild type and
mutated promoter constructs) using the DMRIE-CTM (1,2-dimyri-
styloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide) reagent
(Invitrogen) according to the specifications from the manufacturer.
Briefly, cells were kept under serum-free medium for at least 16 h. 2 g
of plasmid DNA and DMRIE-CTM reagent, respectively, were diluted in
500 l of OptiMEM (Invitrogen). Both mixtures were put together and
incubated at room temperature for 30 min. Culture medium was re-
moved and the lipid-DNA overlaid onto cells and incubated overnight.
Subsequently, medium was replaced by RPMI medium (10% FCS) and
after additional 24 h changed to low serum conditions (1% FCS) for
another 24 h. Subsequently, cells were exposed to hypoxic conditions for
indicated time points.
For luciferase assays, total cell extracts were prepared. Briefly, cells
were harvested in 100 l of lysis buffer (50 mM NaMES, pH 7.8, 50 mM
Tris-HCl, pH 7.8, 10 mM dithiothreitol, 2% Triton X-100). The crude cell
lysates were cleared by centrifugation, 50 l of cleared cell extracts
were added to 50 l of luciferase assay buffer (125 mM NaMES, pH 7.8,
25 mM magnesium acetate, 2 mg/ml ATP), and activity was measured
after injection of 50 l of 1 mM D-luciferin (AppliChem, Darmstadt,
Germany) in a Berthold luminometer (Berthold, Bad Wildbach, Germa-
ny). Total protein concentration was measured by the Bradford tech-
nique (Bio-Rad, Mu¨nchen, Germany). The luciferase activities were
normalized on the basis of protein content as well as on -galactosidase
activity of cotransfected Rous sarcoma virus--gal vector. The -galac-
tosidase assay was performed with 20 l of precleared cell lysate ac-
cording to a standard protocol, as described earlier (43). For calculation
of the -fold induction of luciferase activities, parallel cultures under
normoxia and hypoxia were analyzed. Mean  S.D. of four independent
experiments are shown.
To analyze the effect of HIF-1/ARNT on c-Jun-dependent transcrip-
tion, a commercially available trans-reporting system (PathDetect®,
Stratagene, Heidelberg, Germany) was used. This system analyses the
effects of upstream molecules (e.g. signaling kinases) on the transcrip-
tional activity of c-Jun in an in vitro luciferase assay system. In our
experiments, 1F6 melanoma cell were transfected with the fusion trans-
activator plasmid, pFA2-c-Jun, which contains the activation domain of
c-Jun fused with the yeast GAL4 binding domain. The co-transfected
pFR-Luc reporter plasmid carries five tandem repeats of a GAL4 bind-
ing site linked to the firefly luciferase gene. Co-transfection was per-
formed with a combination of both HIF-1/ARNT-carrying plasmids or
an appropriate control plasmid, which was used for mock transfection
(pFC-dbd). Parallel experiments were performed by co-transfection of
mitogen-activated extracellular signal-regulated protein kinase kinase
(MEKK), which served as a positive control. Total cell extracts were
prepared for luciferase assays as described above.
Preparation of Nuclear Extracts and Electrophoretic Mobility Shift
Assays (EMSA)—Melanoma cells (1F6 cell line) were exposed to hypoxic
conditions for 1, 2, 4, 8, and 12 h, respectively. Parallel cultures were
kept under normoxia. Nuclear extracts were prepared as previously
described (17). Briefly, cells were washed with ice-cold phosphate-buff-
ered saline and pelleted. Supernatants were removed, and cells were
resuspended in 500 l of buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1
mM EDTA, 0.1 mM EGTA, 1 mM dithiothreitol, 0.5 mM phenylmethyl-
sulfonyl fluoride) and allowed to swell for 10 min. Cells were pulled
10–15 times through a 26-gauge 3/8 needle for cell membrane disrup-
tion, and nuclei were pelleted in a microcentrifuge. Nuclei were washed
twice in buffer A and resuspended in 50 l of buffer C (20 mM Hepes,
20% glycerol, 0.4 M NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM dithio-
threitol, 0.2 mM phenylmethylsulfonyl fluoride) and incubated on ice for
45 min with occasional shaking. After centrifugation, supernatants
were harvested, frozen, and stored at 70 °C. The following double-
stranded oligonucleotide was used as probe (derived from Cyr61 pro-
moter region including the AP-1 binding sequence (underlined)): 5-A-
ATATTCCTGACTCAGAGACACA-3 and 5-TGTGTCTCTGAGTCAG-
GAATATT-3. In control experiments a commercially available STAT-1
probe (sc-2573; Santa Cruz Biotechnology, Heidelberg, Germany) with
the following sequence was used (STAT-1 binding sequence under-
lined): 5-CATGTTATGCATATTCCTGTAAGTG-3 and 5-CACTTACA-
GGAATATGCATAACATG-3. For EMSA, 3 g of nuclear proteins were
incubated at room temperature for 20 min in a 20-l binding reaction
mixture containing 20 mM Hepes, 50 mM KCl, 1 mM dithiothreitol, 1 mM
EDTA, 5% glycerol, 2 g of poly(dI-dC), and 50,000–100,000 cpm of
32P-end-labeled probe. The protein/DNA complexes were subjected to
gel electrophoresis on a 5% (or 4% for supershift analyses) non-dena-
turing polyacrylamide gel in 0.5% TBE buffer. The polyclonal rabbit
antibodies -c-Jun (sc-1694 X), -c-Fos (sc-7202 X), -ATF2 (sc-242 X),
-JunB (sc-46 X), -JunD (sc-74 X), anti-STAT3 (sc-482 X), and mouse
monoclonal antibody anti-HIF-1 for supershift analyses were pur-
chased from Santa Cruz Biotechnology. Gels were dried at 80 °C for 1 h
and exposed to HyperfilmTM (Amersham Biosciences) at 70 °C.
Immunoprecipitation and Western Blot Analysis—For immunopre-
cipitation melanoma cells were lysed using a radioimmune precipita-
tion assay lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40,
0.5% sodium deoxycholic acid, 0.1% SDS, 1 mM dithiothreitol, 1 mM
sodium orthovanadate, supplemented with proteinase inhibitors (Roche
Molecular Biochemicals). 500 g of total cellular protein were mixed
with an -c-Jun antibody (sc-1694, rabbit polyclonal antibody; Santa
Cruz Biotechnologies), or an -HIF-1 antibody (sc-13515, mouse mono-
clonal antibody, Santa Cruz Biotechnologies), or as negative control an
-glutathione S-transferase (GST) antibody (sc-459, rabbit polyclonal
antibody; Santa Cruz Biotechnologies), and incubated for 2 h at 4 °C
with occasional shaking. After that, the mixture of cell lysate and
-c-Jun, or -HIF-1 , or -GST antibody were incubated with 30 l of
Protein A-agarose (for -c-Jun and -GST) or Protein G-agarose (for
-HIF-1) (Roche Molecular Biochemicals) for 1 h at 4 °C on an auto-
matic rotator. The mixture was then centrifuged for 5 min at 6000 rpm.
The pellet was resuspended and washed three times using radioim-
mune precipitation assay lysis buffer, followed by one step of washing
with phosphate-buffered saline. Immunoprecipitated proteins were de-
natured in electrophoresis sample buffer for 5 min at 95 °C and sub-
jected to SDS-polyacrylamide gel electrophoresis (PAGE). Gels were
electroblotted onto nitrocellulose membranes (Highbond ECL® , Amer-
sham Biosciences, Braunschweig, Germany) and subjected to immuno-
detection. For detection of HIF-1, the above mentioned mouse mono-
clonal antibody was used; for detection of c-Jun, the above mentioned
rabbit polyclonal antibody was used. Secondary antibodies were cou-
pled to horseradish peroxidase (Pharmingen, Hamburg, Germany; Pro-
mega, Heidelberg, Germany). A standard ECL (enhanced chemilumi-
nescence) reaction (Amersham Biosciences) was performed for signal
visualization.
Statistical Analysis—The data of -fold changes of luciferase activity
in in vitro luciferase assays are given as mean  S.D. Student’s t test
was performed for statistical analysis, and p  0.05 was regarded as
statistically significant.
RESULTS
Microarray Analysis of Hypoxia-inducible Genes Identifies
Cyr61 as a New Hypoxia-inducible Angiogenesis Factor with
Tumor Stage-dependent Expression—The HuFL oligonucleo-
tide microarray carrying 5600 full-length characterized genes
was used for expression profiling of hypoxic melanoma cells of
different aggressiveness. Genes that showed hypoxia-induced
expression in at least one out of five cell lines were included in
the further analyses. By means of this pre-selection step, 1349
hypoxia-inducible genes were identified. These where sub-
jected to further cluster analysis as recently described by Eisen
and co-workers (38). Hierarchical clustering using the -fold
increase of gene expression as clustering parameter generated
four different functional clusters. Cluster one contained 33
genes, cluster two contained 11, cluster three 62, and cluster
four 54 genes, for an overall total of 160 genes. One cluster
(cluster IV) was analyzed in more detail as, in this cluster,
genes displayed hypoxia-inducible gene expression in the low
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aggressive cell lines (530, 1F6; Fig. 1A, two left columns), de-
creased expression in the cell line of intermediate aggressive-
ness (Mel57; Fig. 1A, median column), and no or little change in
gene expression in the highly aggressive cell lines (MV3, BLM;
Fig. 1A, two right columns). This expression pattern was highly
suggestive for genes that may have undergone a selection proc-
ess. These genes and their products might thus be of impor-
tance for tumor progression. Within this cluster two new an-
giogenesis factors for malignant melanoma, Cyr61 and B61
(ephrin-A1) were identified. Re-clustering of cluster IV was
performed using the average differences (which represent the
absolute expression levels of genes) as clustering parameter
(Fig. 1B). These analyses further underlined the outstanding
role of Cyr61. Cyr61 was indeed one of a very few genes that
showed constitutive high absolute expression in the aggressive
cell lines (MV3 and BLM) both under normoxia and hypoxia
(Fig. 1B). Absolute values of B61 (ephrin-A1) expression were
comparatively low. Interestingly, well known hypoxia-induc-
ible angiogenesis factors such as angiogenin, VEGF, and IL-8
did not cluster in the mentioned clusters (data not shown).
However, as expected these angiogenesis factors were found
among the total set of 1349 hypoxia-inducible genes. The non-
clustering of angiogenin, VEGF, and IL-8 might be explained
by the fact that these three angiogenesis factors showed no
particular tumor stage-dependent up-regulation under hy-
poxia. Taken together, the expression pattern of Cyr61 in the
presented analyses was suggestive for an important role of this
angiogenesis factor in malignant melanoma.
FIG. 1. Microarray analysis and gene clustering of hypoxia-inducible genes in malignant melanoma cell lines. The melanoma cell
lines 530, 1F6, Mel57, MV3, and BLM (representing different stages of tumor progression) were exposed to 1% hypoxia for 24 h. Control cultures
were kept under normoxia. Gene chip hybridization on oligonucleotide microarrays was performed using the HuFL gene chip (Affymetrix®)
carrying 5.600 full-length characterized genes. Hierarchical clustering (for details, see “Materials and Methods”) was performed after pre-selection
of genes for those which showed inducible expression under hypoxia in at least one out of five cell lines. A, cluster analysis of gene cluster IV. This
cluster showed the most striking expression pattern in terms of stage-dependent gene expression. The -fold increase of gene expression under
hypoxia compared with normoxia was used as clustering parameter. B, re-clustering of cluster IV using the absolute values of gene expression from
microarray data as parameter for clustering. In A, red squares indicate the degree of up-regulated gene expression, and green squares indicate the
degree of down-regulated gene expression upon hypoxia. Maximum and minimum values of -fold changes are given under the standard color bar.
In B, red and green squares indicate the degree of absolute gene expression compared with mean of all genes analyzed in this experiment.
Maximum and minimum values are given under the standard color bar. Numbers in A and B above the clusters indicate the melanoma cell lines:
1, 530; 2, 1F6, 3, Mel57; 4, MV3; 5, BLM. N, normoxia; H, hypoxia; acc., GenBankTM accession number.
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Cyr61 mRNA Is Induced by Hypoxia in a Time-dependent
Manner and Shows Tumor Stage-dependent Expression—To
further substantiate our microarray analyses, time-course ex-
periments were performed for Cyr61 expression using North-
ern blot analysis. A Cyr61 cDNA probe was generated by re-
verse transcriptase-PCR as described in the Materials and
methods section. As shown in Fig. 2A, Cyr61 mRNA expression
was inducible as early as 12 h after exposure of 1F6 melanoma
cells to hypoxia and showed strong up-regulation at 36 h.
Northern blots of all five melanoma cell lines before and after
exposure to 24 h of hypoxia confirmed that Cyr61 was inducible
by hypoxia in the low aggressive cell line 1F6 (Fig. 2B). In
contrast, it showed down-regulation in the cell line of interme-
diate aggressiveness, Mel57. Constitutive high expression,
which was not further inducible by hypoxia, was observed in
the two highly aggressive variants of melanoma cell lines, BLM
and MV3. Together, these data confirm the hypoxia inducibility
of Cyr61 gene expression and the differential expression de-
pendent on the tumor stage of the melanoma cell lines.
AP-1 and HIF-1 Are Involved in the Transcriptional Regu-
lation of Cyr61 under Hypoxia—To address the question of the
molecular mechanisms underlying enhanced Cyr61 gene ex-
pression under hypoxia, reporter gene analyses were per-
formed using Cyr61 promoter luciferase constructs. As shown
in Fig. 3A, hypoxia significantly induced Cyr61 promoter ac-
tivity in 1F6 melanoma cells (cyr-900-luc construct). Hypoxic
gene induction was completely abolished in experiments using
the cyr-900APmut-luc construct where the AP-1 binding motif
at position 624 is mutated (see “Materials and Methods”).
Essentially the same results were obtained using the truncated
promoter construct (cyr-600-luc), carrying promoter sequences
starting immediately downstream of the AP-1 binding site
reaching to the transcriptional start site. Thus, hypoxia-in-
duced transcription appears to be critically dependent on an
intact AP-1 binding motif conferring AP-1 transcription factors
a central role in hypoxic gene induction of Cyr61. Mutations in
all four HRE-like motifs in the Cyr61 promoter (construct
termed cyr-900HIFmut-luc) had no influence on its activity
under hypoxia. This construct still displayed strong inducibil-
ity under hypoxic conditions (Fig. 3A). Essentially the same
results were obtained by use of constructs with single muta-
tions of each of the four HRE-like motifs (data not shown). To
rule out that constitutive high expression of Cyr61 mRNA in
MV3 and BLM melanoma cells might be the result of mutations
in the AP-1 binding motif, this region was sequenced in all cell
lines. No mutations could be detected in the AP-1 binding motif
in all five melanoma cell lines (data not shown).
To further investigate the putative role HIF-1/ARNT for
Cyr61 transcriptional regulation, co-transfection of 1F6 cells
with both HIF-1 and ARNT carrying plasmid constructs was
performed. As shown in Fig. 3B, co-transfection of HIF-1 and
ARNT led to a strong induction of the luciferase activity of the
cyr-900-luc construct (up to 3.5-fold). Isolated transfection with
each of both factors, HIF-1 or ARNT, induced significant,
however, much lower promoter activation (1.5–2-fold). The use
of the mutated construct and the truncated version of the
Cyr61 promoter, cyr-900APmut-luc and cyr-600-luc, respec-
tively, dramatically reduced promoter activity. However, the
truncated promoter construct remained slightly responsive to
co-transfected HIF-1/ARNT. The promoter construct with the
four mutated HRE-like binding motifs, cyr-900HIFmut-luc,
was still strongly inducible by co-expression of HIF/ARNT
(Fig. 3B).
The influence of HIF-1 on Cyr61 gene regulation was fur-
ther studied in H-Ras-transformed wild type mouse embryonic
fibroblasts (MEF-HIF/) and HIF-1-null mouse embryonic
fibroblasts (MEF-HIF/) (31). Fig. 3C shows that wild type
cells responded to experimentally induced hypoxia with an
induction of the Cyr61 promoter using the cyr-900-luc con-
struct. In contrast, however, both the cyr-900APmut-luc and
cyr-600-luc construct were not inducible by hypoxia. Interest-
ingly, in HIF-1 null cells (MEF-HIF/), the Cyr61 promoter
constructs were not hypoxia-inducible. Taken together, these
data suggest that AP-1 transcription factor binding is critical
for hypoxic gene induction of Cyr61, and both AP-1 and HIF-
1/ARNT may interact.
EMSA Analysis Shows That c-Jun Is the Major Component of
Hypoxia-induced AP-1 Binding—EMSA analyses were per-
formed to further investigate whether AP-1 complexes are in-
duced by hypoxia in 1F6 melanoma cells and to identify tran-
scription factor subunits that might contribute to hypoxia-
induced gene expression. The molecular probe used for EMSA
analyses was derived from the Cyr61 promoter, harboring the
AP-1 binding motif at position 624. As shown in Fig. 4A,
under normoxic conditions low constitutive binding was ob-
served in the upper AP-1 protein/DNA complex (complex I),
which was strongly inducible after 4, 8, and 12 h, respectively,
of hypoxia. The lower complex (complex II) showed no changes
under hypoxia. Supershift analyses using a series of antibodies
directed against components of the AP-1 complex revealed that
the hypoxia-inducible complex contained c-Jun as a major com-
ponent (Fig. 4B). An -STAT3 antibody served as negative
control in supershift analyses and did not supershift both com-
plexes (Fig. 4B). The AP-1 complex could also be supershifted
using a monoclonal antibody against HIF-1 (Fig. 4C). A slight,
but clearcut band appeared immediately above the super-
shifted c-Jun band (Fig. 4C, lanes 2 and 3). A commercially
available molecular probe for STAT-1 served as negative con-
trol for hypoxic induction of transcription factor binding (Fig.
FIG. 2. Northern blot analysis of hypoxia-induced Cyr61 ex-
pression in melanoma cell lines. Melanoma cell lines 530, 1F6,
Mel57, MV3, and BLM were exposed to 1% hypoxia for indicated times
(H12, H24, H36). Control cultures were kept under normoxia (N). Total
RNA was extracted and used for Northern blot hybridization. A, time
course of Cyr61 mRNA expression in 1F6 melanoma cells exposed to
indicated times of hypoxia. B, Cyr61 mRNA expression in melanoma
cell lines of different aggressiveness under normoxia (N) or 24 h of
hypoxia (H). 530 and 1F6 are both low aggressive, non-metastatic
variants, Mel57 is a cell line of intermediate aggressiveness, and MV3
and BLM are both highly aggressive, metastatic variants. L28 Northern
blots are shown (lower panel in A and B) to confirm equal loading
of RNA.
Microarray Analysis of Hypoxia-inducible Genes 45655
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung on July 3, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
4D). None of the two STAT-1 protein/DNA complexes (com-
plexes I and II) was inducible by hypoxia. Further EMSA
experiments were performed for PMA-stimulated 1F6 mela-
noma cells and PMA-stimulated Jurkat cells. These experi-
ments were carried out to demonstrate specificity of c-Jun
supershifts in hypoxia-stimulated 1F6 melanoma cells. As
shown in Fig. 4E, supershift analysis detected c-Jun and JunB
as major components of the AP-1 complex in PMA-stimulated
1F6 melanoma cells. In PMA-stimulated Jurkat cells, the
shifted complex contained c-Fos and JunB as major compo-
nents (Fig. 4F). Further EMSA experiments were performed
with two probes carrying the core binding motif and flanking
sequences of the HRE-like motifs at position 371 and 400 of
the Cyr61 promoter, respectively. Neither showed enhanced
HIF binding under hypoxia in EMSA (data not shown). How-
ever, by use of a commercially available probe carrying the
classical HRE binding motif, strong induction of HIF binding
was observed (data not shown). Taken together, in melanoma
cells hypoxia induces binding of an AP-1 complex to the AP-1
binding motif in the Cyr61 promoter. This hypoxia-inducible
complex contains c-Jun and HIF-1.
HIF-1 Interacts with the AP-1 Transcription Factor via
Binding to c-Jun—The presented findings of the in vitro lucif-
erase assays were highly suggestive for a direct interaction of
both transcription factors HIF-1 and c-Jun/AP-1. To further
address this question, immunoprecipitation studies were per-
formed using -c-Jun as primary antibody to immunoprecipi-
tate HIF-1 in cellular extracts of hypoxic melanoma cells. For
this purpose 1F6 melanoma cells were transfected with a com-
bination of c-Jun, HIF-1, and ARNT carrying plasmid con-
structs. As shown in Fig. 5, under normoxia no HIF-1 protein
could be immunoprecipitated with an -c-Jun antibody in 1F6
melanoma cells. However, after 4 h of hypoxia, a strong signal
for immunoprecipitated HIF-1 was detected (Fig. 5). Parallel
performed Western blots of whole cell lysates for HIF-1
showed HIF-1 expression under normoxia with a slight in-
crease in expression after 4 h of hypoxia. In the reciprocal
experiments using an -HIF-1 antibody to immunoprecipitate
c-Jun, strongly increased expression of immunoprecipitated
c-Jun was observed after 4 h of hypoxia compared with nor-
moxia. The amount of c-Jun protein in whole cell lysates was
similar under normoxia and hypoxia. Immunoprecipitation
with an antibody against glutathione S-transferase (GST)
served as negative control and immunoprecipitated neither
HIF-1 nor c-Jun (data not shown). Taken together, these data
suggest that c-Jun and HIF-1 interact in melanoma cells
under hypoxia and that this interaction might contribute to
Cyr61 gene regulation.
HIF-1 Directly Interferes with c-Jun-dependent Transcrip-
tion—To further substantiate our findings that HIF-1/ARNT
might functionally interact with c-Jun and impact on c-Jun-de-
pendent transcription, a commercially available c-Jun-depend-
luc, Cyr600-luc, Cyr-900APmut-luc, and Cyr900HIFmut-luc promoter
luciferase constructs, respectively. -Fold increase of firefly luciferase
activity in cell extracts after co-transfection with HIF-1 and ARNT
carrying plasmids alone or in combination is shown. Transfection with
empty vector (mock transfection) served as control. C, wild type mouse
embryonic fibroblasts (MEF-HIF/) and HIF-1 null mouse embry-
onic fibroblasts (MEF-HIF/) were exposed to different times of hy-
poxia. -Fold increase of firefly luciferase activity in cell extracts of
MEF-HIF/ and MEF-HIF/ under hypoxia compared with paral-
lel cultures under normoxia is shown. The luciferase activities in A–C
were normalized on the basis of protein content and -galactosidase
activity of co-transfected Rous sarcoma virus--gal vector. Mean and
standard deviations of four independent experiments are shown. Sta-
tistical significances of differences between base-line and induced lucif-
erase activity are indicated by asterisks; p  0.05.
FIG. 3. Firefly luciferase assays of melanoma cells and mouse
embryonic fibroblasts exposed to hypoxia using Cyr61 pro-
moter luciferase constructs. A, 1F6 melanoma cells were transfected
with 2 g of Cyr-900-luc, Cyr600-luc, Cyr-900APmut-luc, and
Cyr900HIFmut-luc promoter luciferase constructs, respectively. Mela-
noma cells were exposed to different times of hypoxia as indicated (H8,
H16, H24). Control cultures were kept under normoxia (N). -Fold in-
crease of firefly luciferase activity in cell extracts of 1F6 melanoma cells
under hypoxia compared with parallel cultures under normoxia is
shown. B, 1F6 melanoma cells were transfected with 2 g of Cyr-900-
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ent trans-reporting system was used. In vitro luciferase assays
were performed using a luciferase construct where five tandem
repeats of yeast GAL4 bindings sites are fused with the lucif-
erase gene. Co-transfection was performed with plasmid vec-
tors carrying a c-Jun/GAL4 fusion protein and different con-
centrations of HIF-1/ARNT. Parallel performed experiments
with MEKK or empty vector served as positive or negative
controls. As shown in Fig. 6, co-transfection of HIF-1/ARNT
dramatically increased luciferase activity in a concentration-
dependent manner (up to 10-fold). The maximum level of pro-
moter activity reached by HIF/ARNT co-transfection was sim-
ilar to that of induction by MEKK, which served as a positive
control. To rule out nonspecific activation of the promoter con-
struct by HIF-1/ARNT transcription factors, assays were per-
formed without the c-Jun/GAL4 fusion protein. Under these
conditions, the promoter base-line activity decreased and was
not inducible by co-expression of HIF/ARNT (Fig. 6). Taken
together, these results strongly argue for an interaction be-
tween HIF-1/ARNT and c-Jun, which leads to a strong induc-
tion of c-Jun-dependent transcription.
FIG. 4. EMSA for AP-1 and STAT-1 of nuclear extracts from 1F6 melanoma cells and Jurkat cells under normoxia and hypoxia. A,
melanoma cells were exposed to hypoxia for 1, 2, 4, 8, and 12 h (H1, H2, H4, H8, and H12, respectively). Control cultures were kept under normoxia
(N). For EMSA of AP-1, the following 32P-labeled double-stranded oligonucleotide derived from the Cyr61 promoter region was used: 5-
AATATTCCTGACTCAGAGACACA-3 (AP-1 binding sequence underlined). Competition experiments were carried out with 10- and 100-fold,
respectively, molar excesses of cold probe. B, AP-1 complexes of 1F6 cells after 8 h of hypoxia were analyzed by supershift analysis using -c-Jun,
-c-Fos, -ATF2, -JunB, -JunD, and anti-STAT3 Abs, respectively. C, AP-1 complexes of 1F6 cells after 8 h of hypoxia were analyzed by
supershift analysis using -c-Jun and anti-HIF-1 Abs, respectively. D, for EMSA of STAT-1 (control experiments), the 32P-labeled double-stranded
oligonucleotide had the sequence 5-CATGTTATGCATATTCCTGTAAGTG-3 (STAT-1 binding sequence underlined). Competition experiments
were carried out with 10- and 100-fold, respectively, molar excesses of cold probe. E, AP-1 complexes of 1F6 melanoma cells induced by stimulation
with PMA for 4 h were analyzed by supershift analysis using -c-Jun, -c-Fos, -ATF2, -JunB, and -JunD Abs, respectively. F, AP-1 complexes
of Jurkat cells induced by stimulation with PMA for 4 h were analyzed by supershift analysis using the same Abs as in E. Free probe is indicated.
n.s., nonspecific. I and II, complexes I and II.
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DISCUSSION
Rapidly growing tumors and tumor metastases are exposed
to hypoxic or even anoxic conditions in the tissue microenvi-
ronment. Hypoxia in turn has a profound influence on tumor
pathophysiology, leading to enhanced tumor aggressiveness
(Refs. 44–47; for review, see Ref. 11). Although tissue hypoxia
is a well documented phenomenon for a wide variety of tumors,
our understanding of the hypoxic tumor cell response is far
from being complete. More recent interest focused on hypoxia-
induced genes that contribute to tumor angiogenesis, a major
prerequisite for enhanced tumor growth.
In the present report we used the oligonucleotide microarray
technique for mRNA expression profiling of malignant mela-
noma cell lines to achieve a more complete understanding of
the hypoxic tumor cell response of this tumor. Five cell lines of
different aggressiveness were analyzed, and a special emphasis
was put on the identification of factors involved in tumor an-
giogenesis. It could be shown by use of hierarchical gene clus-
tering methods (38) that hypoxia-inducible genes clustered in
four different gene clusters, overall encompassing 160 different
genes. In searching for angiogenesis factors within these clus-
ters, we identified Cyr61 and ephrin-A1, which clustered in
cluster IV. The gene expression pattern in this cluster was
characterized by gene induction in low aggressive melanoma
cells, down-regulation in a melanoma cell line of intermediate
aggressiveness, and no or only slight changes of gene expres-
sion in highly aggressive melanoma cell lines. Further analysis
of absolute gene expression values in this cluster revealed that
Cyr61 showed constitutive high expression in highly aggressive
cell lines, whereas ephrin-A1 expression values were low and
close to background values. Thus, besides its hypoxia inducibil-
ity, a clear stage-dependent expression of Cyr61 in melanoma
cells could be detected. Moreover, Cyr61 was among the genes
with the highest absolute expression in the highly aggressive
melanoma cell lines.
Cyr61 was initially described as a growth factor-inducible
gene in mouse fibroblasts (48). It belongs to the so-called CCN
family of immediate early genes. The abbreviation CCN stands
for the names of the best known family members: CCN1
(CYR61), CCN2 (CTGF, connective tissue growth factor), and
CCN3 (NOV, or nephroblastoma-overexpressed) (for review,
see Ref. 49). Additional members, CCN4, CCN5, and CCN6,
have been described more recently (49). A characteristic struc-
tural feature of all these proteins is highly conserved cysteine-
rich domains. CCN family members exert a wide variety of
different functions, mainly related to cellular proliferation and
cell adhesion. One of the best characterized factors is in fact
Cyr61. Cyr61 is a secreted protein involved in cellular prolif-
eration, differentiation, DNA synthesis, cell adhesion to extra-
cellular matrix, and angiogenesis (49–53). The receptors me-
diating the diverse functions of Cyr61 have been investigated
in more detail, and it could be shown that Cyr61 binds to
members of the family of integrins, e.g. v3, v5, 2b3, and
61 (54–57). Integrin receptor binding is of importance for
endothelial cell activation and proliferation, but may also ac-
count for the direct effects of Cyr61 on tumor cells and for its
binding to extracellular matrix.
Interestingly, Cyr61 is able to promote tumor formation in
experimental mouse models (41). Furthermore, in accordance
with our findings, it could be shown in more recent experiments
that high Cyr61 expression was associated with an aggressive
phenotype of breast carcinoma cells lines and may play a role
during tissue invasion of breast carcinoma cells (39, 58). From
a functional point of view, these findings may argue for a
selection process in vivo, which finally leads to aggressive phe-
notypes with high Cyr61 expression. It is well accepted that
hypoxia may select for aggressive tumor cell phenotypes (Ref.
FIG. 6. Firefly luciferase assays of 1F6 melanoma cells using a
GAL4-dependent trans-reporting system. 1F6 melanoma cells
were transfected with a plasmid vector carrying a c-Jun-GAL4 fusion
protein consisting of the activation domain of c-Jun fused with the yeast
GAL4 binding domain. The reporter plasmid carried five tandem re-
peats of a GAL4 binding motif linked to the firefly luciferase gene.
Co-transfection was performed with a combination of HIF-1/ARNT
carrying plasmids or pFC-dbd control plasmid (mock transfection).
Whole cell extracts were prepared and luciferase assays were per-
formed as described (see “Materials and Methods”). Mean and standard
deviations of four independent experiments are shown. Statistical sig-
nificances of differences between base-line and induced luciferase ac-
tivity are indicated by asterisks; p  0.05.
FIG. 5. Immunoblots for HIF-1 and c-Jun protein expression
after immunoprecipitation of cell lysates or from whole cell
lysates from melanoma cells exposed to hypoxia. 1F6 melanoma
cells were exposed to hypoxia for 2 h (H2) and 4 h (H4), respectively.
Control cultures were kept under normoxia (N). Cells were lysed, and
total protein was extracted. c-Jun was immunoprecipitated using an
-c-Jun polyclonal antibody and Protein A-agarose. HIF-1 was immu-
noprecipitated using an -HIF-1 mouse monoclonal antibody and
Protein G-agarose. Immunoprecipitated proteins were subjected to
SDS-PAGE and blotted onto nitrocellulose membranes. Immunoblots
were carried out using a monoclonal antibody against HIF-1 (upper
panels) or against c-Jun (lower panels). Immunoblots using whole cell
lysates were performed in parallel. Signal detection was performed by
standard ECL reaction. IP, immunoprecipitation; Ig, rabbit or mouse
immunoglobulin.
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45; for review, see Ref. 11). Because Cyr61 is strongly hypoxia-
inducible, hypoxia might be a central mechanism by which
selection toward high Cyr61 expression occurs. Interestingly,
another member of the CCN gene family, CTGF, has also been
shown to be hypoxia-inducible (59).
The second angiogenesis factor identified in our microarray
analyses was ephrin-A1 (B61 gene). It is well established that
ephrins are major contributors to embryonic vasculogenesis
(60). Their putative role in tumor angiogenesis has been em-
phasized recently (61). The absolute expression levels in mel-
anoma cells in our investigations were comparatively low.
However, ephrin-A1 might play a role in malignant melanoma
as its expression had been shown to be associated with mela-
noma progression (62).
Because Cyr61 might be of importance for melanoma pro-
gression, the transcriptional mechanisms of its regulation un-
der hypoxia were further investigated. By means of reporter
gene analysis and EMSA, we were able to show that both
transcription factors, AP-1 and HIF-1 , may contribute to the
hypoxic induction of Cyr61 in melanoma cells. Interestingly,
the core binding motif for HIF-1 , CGTG, is not present in the
published Cyr61 promoter sequence (41). However, the comple-
mentary sequence of the HIF-1 core binding motif, CACG, is
present four times in the Cyr61 promoter, up- and downstream
of the described AP-1 binding motif at position 624. In our
experiments, mutations in the AP-1 binding motif of the Cyr61
promoter construct totally abolished hypoxia inducibility of the
reporter gene constructs. In contrast, mutation of all for HRE-
like motifs had no influence and transcriptional activity under
hypoxia in melanoma cells. However, the presence of HIF-1
might be of critical importance for Cyr61 transcription, because
the Cyr61 promoter was not responsive to hypoxia in mouse
embryonic fibroblasts lacking the HIF-1 gene. Similar results
have been recently published by others (63). It had been shown
that c-Jun/AP-1-dependent transcription may critically de-
pendent on the presence of HIF-1 (63). In immunoprecipita-
tion and EMSA studies, we could further show that under
hypoxia HIF-1 directly binds to c-Jun/AP-1 and may thereby
interfere with Cyr61 gene activation. These findings are in
accordance with very recent data presented by Alfranca and
co-workers (64), who showed that HIF-1 and AP-1 may di-
rectly interact. The current knowledge about interaction part-
ners (in particular transcription factors and transcriptional
co-activators) of HIF-1 has recently been summarized (27).
We could further show by GAL4-dependent reporter gene as-
says that co-expression of HIF/ARNT dramatically induced
c-Jun-dependent transcription, similar to that observed in pos-
itive control experiments with MEKK. This further argues for
an interaction between c-Jun/AP-1 and HIF/ARNT in hypoxic
gene regulation.
Taken together, in the present report, we show that Cyr61 is
hypoxia-inducible and shows tumor stage-dependent expres-
sion in malignant melanoma cells. Based on our findings of the
microarray analyses, Cyr61 may have an outstanding role in
malignant melanoma. The described mechanisms of transcrip-
tional regulation point to new targets for interference with
tumor progression. In particular, HIF-1may be an interesting
target for future melanoma therapy. Indeed, it had been shown
that inhibition of HIF-1 activity by antisense technique was
able reduce aggressive tumor growth in vivo (65).
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